Project description
Innovative solution for type 1 diabetes
Type 1 Diabetes (T1D) is an auto-immune disease that destroys the insulin-producing beta cells of the pancreas. T1D affects 20 million people worldwide, half of whom are diagnosed before the age of 20, and causes severe complications and even death. T1D patients need to manage their condition daily. The EU-funded D2P project and coordinator Diabeloop have refined Diabeloop’s Automated Insulin Delivery system, regulating glucose by continuously calculating the most personalised and adequate insulin dose and automatically delivering it to the patient. The solution relies on Artificial Intelligence algorithms and integrates a telemonitoring programme through highly secured data exchange. Diabeloop’s solution is designed to improve short-term and long-term clinical outcomes while significantly improving patients' quality of life.
Objective
20 million people worldwide are affected by type 1 diabetes (T1D), an autoimmune condition leading to the destruction of beta cells of the pancreas producing insulin. T1D causes severe complications: short terms - seizures and fainting that could result in coma or even death; long terms - blindness, amputations, renal failure, heart diseases. T1D can occur to anyone and half of the cases begin before age 20. T1D patients have to manage their diabetes on a daily basis, facing countless stressful situations.
Diabeloop’s “artificial pancreas” solution aims to mimic the glucose regulating function of a healthy pancreas. The core of our “artificial pancreas” solution is an artificial intelligence: algorithms based on physiological models continuously calculate the most appropriate and personalised dose of insulin. Insulin is then automatically delivered to the patient. Diabeloop goals are to reduce hypoglycaemia and hyperglycaemia periods, alleviate the day-to-day burden and avoid long-term complications.
Diabeloop’s first generation solution (DBLG1) is integrated in a closed-loop system made of three components: a continuous glucose monitoring sensor, a connected insulin pump, and a handset hosting algorithms and controlling the pump. Diabeloop’s solution integrates a telemedicine program through highly secured data exchange, storage and healthcare professional identification. Clinicians may access the patients’ data and suggest treatment adjustments as necessary, for an improved system customisation and long-term regulation.
During the phase 2 project, we scale up and target a European adoption of our breakthrough innovation. We focus on France, the Netherlands and Sweden, 3 countries with complementary specificities to validate our model: adaptation of the device to foreign market, optimisation of performances, telemonitoring upgrade and industrialisation.
Fields of science
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- natural sciencescomputer and information sciencesartificial intelligence
- medical and health sciencesclinical medicineendocrinologydiabetes
- engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensors
- natural sciencescomputer and information sciencesdata sciencedata exchange
- medical and health sciencesmedical biotechnologytissue engineeringartificial pancreascontinuous glucose monitors
Programme(s)
Funding Scheme
SME-2 - SME instrument phase 2Coordinator
38028 GRENOBLE
France
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.